Trim 55-60% of UNH position to 40-45% residual with $345 stop and $380 collar ahead of Q3 2026 catalyst cluster; exit the alpha-destructive 40-50% middle-ground zone decisively
Trim 55-60% of UNH position to 40-45% residual (exit the alpha-destructive 40-50% middle-ground zone), with $345 hard stop (200 SMA structural invalidation level) and $380 put collar at ~25% notional defining downside through Q3 2026 binary catalysts. Upgrade to Hold on confirmed $411.74 close with volume ≥5M and MACD line positive, or Q3 EPS >$6.50 with margin ≥7.5% and benign MLR, or buyback re-initiation. Downgrade to Sell on close below $375, Q3 EPS <$5.50, guidance cut, or CMS Final Rate Notice showing >2% payment compression. The 09-02 binding lesson and 09-03 reflection mandate explicit directional sizing rather than passive benchmark carry into this structurally identical no-man's-land setup with unresolved catalyst stack.
| Position | Action |
|---|---|
| Ahead of Q3 2026 catalyst cluster (October 1 PA-removal, Q3 earnings mid-October, potential buyback re-initiation) | Trim 55-60% of UNH position, leaving 40-45% residual |
| Residual position 40-45% through binary window | Collar hedge with $380 puts at ~25% of residual notional to define downside |
| Confirmed close above $411.74 on volume ≥5M AND MACD line crossing positive (not just histogram) | Re-enter / upgrade position |
| Current price ~$397 below declining 50 SMA at $411.74 for ~22 sessions, MACD line still negative at -3.47 | Maintain underweight sizing; do not passively carry benchmark weight |
UNH has completed its margin recovery with Q1 2026 operating margins at 8.0%, making the stock a normalized earnings story trading at a recovery multiple of 17.7x forward P/E with multiple catalysts ahead.
| Indicator | Value | Signal |
|---|---|---|
| RSI | 46.82 | neutral |
| MACD | -3.47 | neutral |
| MACD Signal | -4.61 | neutral |
| MACD Histogram | +1.14 | bullish |
| 10 EMA | 396.96 | neutral |
| 50 SMA | 411.74 | bearish |
| 200 SMA | 349.14 | bullish |
| VWMA | 394.84 | bullish |
| Bollinger Upper | 408.72 | neutral |
| Bollinger Middle | 396.91 | neutral |
| Bollinger Lower | 385.11 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
↩ rebuts: “Bear 'mixed valuation' and GST concerns”
EV: +13.6% to +16.1%
Q1 2026 is a single data point against a backdrop of structural damage—two years of declining earnings, a still-depressed TTM operating margin of 7.13% (158bps below the 2023 baseline of 8.71%), suspended capital return programs, negative tangible book value, and a stock unable to reclaim its 50 SMA for 22 sessions. The bull is buying hope; the bear is waiting for proof.
EV: -15% (bear scenario: 10% multiple compression to 16x + 5% EPS miss = 15% downside from current levels) · concedes: Q1 2026 EPS of $6.90 and 8.0% operating margin are genuine strong prints that could signal the start of recovery; The 200 SMA at $349.14 represents intact long-term support; UNH has $24B in FCF generating capacity; October 1 PA removal may improve provider relations and reduce administrative burden; Hemsley's operational discipline could accelerate cost control initiatives; The stock did bounce from the $383.83 lower band test
→ vs conservative: The conservative '1:1 risk/reward' framing is lazy math—the $450-460 target is the July 16 high from seven weeks ago, not an invented aspiration, and the bear case requires four independent failures versus one catalyst landing for the bull case
→ vs conservative: Applying a hawkish-rates framework to UNH is exactly the wrong playbook—UNH is a 0.63 beta defensive mega-cap with 2.31% dividend yield that benefits from capital rotation INTO healthcare when growth names get hammered
→ vs conservative: Waiting for margin to fully catch up is a reason to be patient, not sidelined—the Q1 2026 EPS of $6.90 confirms the recovery is happening; the question is slope, not direction
→ vs neutral: Waiting for $411.74 daily close with volume means buying at $415 and missing the first 5% of the move—the whole point of high-conviction setups is positioning before the obvious trigger fires
→ vs conservative: Reading the tape like we're still in distribution is wrong—volatility compression + rising MACD histogram + price holding 200 SMA and VWMA is accumulation, not distribution
| ATR | 8.65 | bullish |
Support: 394.84 · 385.11 · 349.14 | Resistance: 402.23 · 408.72 · 411.74 · 461.62
UNH closed at $397.14 on 9/04 with OHLC of 397.05/402.23/395.23/397.14 and volume of 4.83M. The stock has transitioned from a powerful uptrend (Aug 2025 to Jul 2026 high of $461.62) through a ~16% correction bottoming at $383.83 on 8/20, now stabilizing in a sideways consolidation. Long-term trend remains bullish (price $48 above rising 200 SMA at $349.14), medium-term is bearish (price $14.60 below declining 50 SMA at $411.74), and short-term is neutral (price essentially flat with 10 EMA at $396.96). RSI recovered from oversold territory (33.32 on 8/20) to 46.82, while MACD histogram has been expanding (+1.14) but the MACD line (-3.47) has not yet crossed above the signal line (-4.61). Bollinger Bands have compressed significantly (range contracted from ~31 points in early August to ~23.6 points currently), with price sitting precisely on the middle band at 396.91 — a coiled-spring setup. ATR has declined 30% from ~12.36 to 8.65, indicating normalized volatility. The report recommends HOLD, with the 50 SMA reclaim ($411.74+) as the bullish trigger and a close below $385 as the bearish exit. Stop-loss is recommended near $384.
Market Cap
$356.5B
P/E (TTM)
25.5x
Forward P/E
17.7x
PEG Ratio
1.08
P/B
3.65x
EPS (TTM)
$15.56
Forward EPS
$22.44
Dividend Yield
2.31%
Beta
0.63
Free Cash Flow (TTM)
$24.3B
52-Week High
$461.62
52-Week Low
$255.97
Revenue FY2022
$324.2B
Revenue FY2023
$371.6B
Revenue FY2024
$400.3B
Revenue FY2025
$447.6B
Net Income FY2022
$20.12B
Net Income FY2023
$22.38B
Net Income FY2024
$14.41B
Net Income FY2025
$12.06B
Diluted EPS FY2022
$21.18
Diluted EPS FY2023
$23.86
Diluted EPS FY2024
$15.51
Diluted EPS FY2025
$13.23
Q1 2025 Revenue
$109.6B
Q1 2025 Net Income
$6.29B
Q1 2025 Diluted EPS
$6.85
Q1 2025 Operating Margin
8.3%
Q2 2025 Revenue
$111.6B
Q2 2025 Net Income
$3.41B
Q2 2025 Diluted EPS
$3.74
Q2 2025 Operating Margin
4.6%
Q3 2025 Revenue
$113.2B
Q3 2025 Net Income
$2.35B
Q3 2025 Diluted EPS
$2.59
Q3 2025 Operating Margin
3.8%
Q4 2025 Revenue
$113.2B
Q4 2025 Net Income
$0.01B
Q4 2025 Diluted EPS
$0.01
Q4 2025 Operating Margin
0.3%
Q1 2026 Revenue
$111.7B
Q1 2026 Net Income
$6.28B
Q1 2026 Diluted EPS
$6.90
Q1 2026 Operating Margin
8.0%
Operating Margin (TTM)
7.13%
Operating Margin FY2025
4.24%
Profit Margin (TTM)
3.14%
ROE (TTM)
14.15%
ROA (TTM)
4.87%
EBITDA FY2025
$23.1B
EBITDA (TTM)
$26.7B
Total Assets (Mar 2026)
$312.6B
Total Liabilities (Mar 2026)
$207.3B
Stockholders' Equity (Mar 2026)
$97.9B
Total Debt (Mar 2026)
$77.9B
Net Debt (Mar 2026)
$49.9B
Cash & Equivalents (Mar 2026)
$28.0B
Goodwill & Intangibles (Mar 2026)
$130.6B
Tangible Book Value (Mar 2026)
-$32.7B
Debt/Equity (Calc) (Mar 2026)
0.80x
Operating Cash Flow FY2025
$19.7B
CapEx FY2025
-$3.6B
Free Cash Flow FY2025
$16.1B
Dividends Paid FY2025
-$7.9B
Share Repurchases FY2025
-$5.5B
Acquisitions FY2025
-$4.5B
Q1 2026 Operating Cash Flow
$8.9B
Q1 2026 Free Cash Flow
$8.1B
Annual Dividend Per Share
~$9.00
Total Shareholder Yield (TTM)
~4.5%
Dividend Growth CAGR (2022-2025)
~9.7%
Strengths
Concerns
UNH is a healthcare bellwether trading at a forward P/E of 17.7x with TTM metrics depressed by an anomalous Q4 2025 (net income essentially $0) and lingering Change Healthcare cyberattack charges ($8.31B in 2024), but Q1 2026 recovery ($6.90 EPS, 8.0% operating margin) suggests normalization is underway. Revenue grew +11.8% to $447.6B in FY2025, yet net income fell -16.3% to $12.06B due to elevated Medicare Advantage medical loss ratios and one-time items; TTM EPS of $15.56 is down ~45% from the $23.86 peak in 2023. The balance sheet remains investment-grade with $49.9B net debt and 0.80x D/E, though tangible book value is deeply negative at -$32.7B due to $130.6B in goodwill from M&A. Free cash flow of $24.3B TTM supports the 2.31% dividend yield and UNH's Dividend Aristocrat status, but buybacks remain suspended — a key catalyst to watch for EPS acceleration.
Macro: Macro backdrop is turning less friendly for UNH: August jobs report blowout + rising bond yields have effectively shut the door on Fed cuts in 2026 (Sept: 0%, Oct: 4%, Dec: 6%). The December cut probability fell 4.5pp in one week — the most actionable signal. Gold holding near $4,500 (safe-haven/inflation hedge bid), silver rallying into jobs print. Dow fell 419 points on yield-driven selling. No 2026 healthcare-policy prediction markets exist on Polymarket. FRED macro series (CPI, core PCE, 10Y, fed funds, unemployment) unavailable this session — macro commentary grounded in prediction-market odds and news flow.